NCT06023797View on ClinicalTrials.gov

Neoadjuvant Immunochemotherapy for Lung Cancer

CompletedOBSERVATIONAL
Enrollment

83

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

November 30, 2022

Study Completion Date

July 31, 2023

Conditions
Lung Cancer
Interventions
DRUG

Neoadjuvant immunochemotherapy

Patients who received NAICT and were operated at the Department of Thoracic Surgery, Zhongshan Hospital Fudan University between 2017 and 2022.

Trial Locations (1)

200032

Zhencong Chen, Shanghai

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER

NCT06023797 - Neoadjuvant Immunochemotherapy for Lung Cancer | Biotech Hunter | Biotech Hunter